Study of Irinotecan,Oxaliplatin, and S1 in Patients With Advanced Pancreatic Cancer

Sponsor
Qingdao Central Hospital
Study ID
NCT03726021
Phase
PHASE2
Status
Completed

Conditions

  • Overall Survival

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Irinotecan,Oxaliplatin, and S1 — DRUG
    Drug: Irinotecan is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells. Drug: Oxalipatin Oxaliplatin is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells Drug: S1 is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells

Study Details

To identify the efficiency of Irinotecan, Oxaliplatin, and S1 in patients with previously untreated local regional or metastatic pancreatic cancer.

Key Dates

Start date
Jan 26, 2018
Status verified
Mar 2023
Primary completion
Dec 31, 2022
Completion
Feb 28, 2023

Study Design

Enrollment
47 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: experimental arm
    Treatment consists of treatment with Irinotecan 165mg/m2, Oxaliplatin 85mg/m2 on day 1, and S1 40mg orally on day 1-14, every 21 days each cycle. Treatment will be administered until untolerable toxicities or progression or subject death, or either the subject or sponsor discontinues the study.

Primary Outcome Measure

The overall survival in this population of patients. [ Time Frame: Time Frame: 2 years ]

Related Studies